Therapeutic Decision-Making for Autoimmune Disease in Dogs

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Glucocorticoids are the foundational first-line induction therapy for most canine autoimmune diseases due to their rapid onset and broad immunosuppressive mechanisms, but their use necessitates careful monitoring for predictable adverse effects like polyuria, polydipsia, and gastrointestinal ulceration.
• Steroid-sparing agents such as calcineurin inhibitors (e.g., cyclosporine), antimetabolites (e.g., azathioprine, mycophenolate mofetil), and pyrimidine synthesis inhibitors (e.g., leflunomide) are selected based on disease characteristics, required speed of onset, organ tolerance, and cost, often used in combination with glucocorticoids for diseases with high relapse rates or requiring prolonged therapy.
• Rescue therapies including intravenous immunoglobulin (IVIG), rituximab, or splenectomy are reserved for refractory or life-threatening cases, aiming to rapidly suppress antibody-mediated destruction or remove sites of autoantibody production while slower-acting agents take effect.
• Therapeutic decision-making is an iterative process requiring frequent monitoring (weekly to monthly during induction, then extended intervals) of efficacy parameters (e.g., PCV for IMHA, platelet count for ITP, lesion scores for pemphigus) and adverse effects (e.g., CBC, biochemistry, urinalysis, blood pressure) to guide stepwise dose reduction over weeks to months, with premature withdrawal being the most common cause of relapse.
• Diagnosis confirmation through methods like direct antiglobulin testing (DAT) via flow cytometry, cytology, or histopathology is critical to ensure immunosuppression is indicated and to exclude differential diagnoses, as empirical treatment without adequate confirmation carries significant risks.
• Infection is the most common cause of treatment-related mortality in immunosuppressed dogs, necessitating vigilant surveillance for clinical signs such as fever, lethargy, or cough, and prompt exclusion of bacterial or opportunistic fungal disease through cultures and imaging before attributing signs to the autoimmune condition.

Autoimmune disease in dogs presents a recurring clinical challenge: the immune system, tasked with defending the host, instead targets self-antigens and drives tissue injury. The therapeutic response must therefore balance effective immunosuppression against the risks of infection, drug toxicity, and metabolic derangement. This article provides a decision framework for selecting and monitoring immunosuppressive therapy in canine autoimmune disease, written for veterinary students and practitioners who already understand the core concepts of clinical immunology. It focuses on the reasoning pathway from diagnosis through drug selection, induction, maintenance, and relapse management, and it deliberately excludes specific milligram per kilogram doses. Current formulary and label references must be consulted before any drug is administered.

The primary clinical question this article answers is practical: given a confirmed or strongly suspected autoimmune diagnosis in a dog, how does the clinician choose among glucocorticoids, calcineurin inhibitors, antimetabolites, and biologic agents, and how does that choice change as the patient responds, relapses, or develops adverse effects? A secondary question concerns monitoring. Autoimmune therapy is not a fixed protocol. It is an iterative process in which drug doses are tapered against disease activity and laboratory parameters, and in which complications are anticipated instead of discovered. The framework presented here applies across the common canine immune-mediated diseases, including immune-mediated hemolytic anemia (IMHA), immune thrombocytopenia (ITP), immune-mediated polyarthritis, and the pemphigus complex, with disease-specific adjustments noted where they matter.

At a Glance

The Pathophysiology Basis for Drug Selection

Autoimmune disease arises from a failure of immune tolerance. Self-reactive lymphocytes escape central or peripheral deletion, become activated, and produce autoantibodies, autoreactive T cells, or both. The effector mechanisms that follow determine both the clinical syndrome and the rational choice of therapy. Antibody-mediated destruction of platelets or erythrocytes, as in ITP and IMHA, is driven by opsonization and phagocytosis, and it responds to drugs that suppress B-cell activity and macrophage function. T-cell-mediated inflammation, as in immune-mediated polyarthritis or inflammatory bowel disease, responds better to agents that inhibit T-cell activation and proliferation.

The diagnosis itself can be challenging. In canine ITP, for example, a definitive antemortem test has historically been elusive. A flow cytometry-based direct antiglobulin test that detects platelet-bound IgG has been evaluated in a large cohort of thrombocytopenic dogs, with a diagnostic cutoff of 10% IgG-bound platelets and a positivity rate of 39.3% in affected animals. Notably, DAT-positive dogs had significantly lower platelet counts than DAT-negative dogs, supporting the test's ability to identify immunologically mediated destruction. This illustrates a broader principle: the more specific the diagnostic test, the more confident the clinician can be in committing to long-term immunosuppression, which carries its own morbidity.

Glucocorticoids as the Foundation

Glucocorticoids remain the backbone of induction therapy for nearly all canine autoimmune diseases. Their mechanism is broad: they suppress proinflammatory cytokine transcription, reduce leukocyte migration, inhibit phagocytosis, and induce lymphocyte apoptosis. The clinical effect is rapid, often visible within 24 to 72 hours, which makes them indispensable in acute, life-threatening presentations such as severe IMHA or ITP with bleeding.

The therapeutic window is narrow. At immunosuppressive doses, glucocorticoids produce predictable adverse effects including polyuria, polydipsia, polyphagia, panting, muscle wasting, and gastrointestinal ulceration. Longer-term use risks iatrogenic hyperadrenocorticism, pancreatitis, and susceptibility to opportunistic infection. The clinician must therefore decide early whether the disease is likely to respond to glucocorticoids alone or whether a steroid-sparing agent should be added. Diseases with high relapse rates, such as pemphigus foliaceus, or those requiring prolonged therapy, such as chronic polyarthritis, generally warrant combination therapy from the outset. The MSD Veterinary Manual provides disease-specific guidance on glucocorticoid protocols and expected response timelines.

Selecting a Steroid-Sparing Agent

The choice of a second-line immunosuppressant depends on four variables: the target disease, the speed of onset required, the patient's organ function, and the owner's capacity for monitoring and cost. Azathioprine, a purine antimetabolite, is widely used for its reliable efficacy in T-cell-mediated disease, but its onset of action is delayed by 2 to 3 weeks, making it unsuitable as sole induction therapy. Mycophenolate mofetil acts faster, within days, and is increasingly used in IMHA and ITP, though it carries a higher risk of gastrointestinal upset. Cyclosporine, a calcineurin inhibitor, is effective across a range of immune-mediated diseases and is particularly useful in dermatologic conditions, but it requires monitoring of blood levels in refractory cases and is expensive at immunosuppressive doses. Leflunomide, a pyrimidine synthesis inhibitor, has a favorable adverse effect profile and is used in immune-mediated polyarthritis and glomerulonephritis, though its use is off-label in dogs.

The evidence base for choosing among these agents is limited. Comparative trials are scarce, and much of the literature consists of retrospective case series. The clinician should therefore rely on a structured approach: identify the dominant effector mechanism, estimate the speed of onset needed, and select the agent with the most favorable toxicity profile for that individual patient. Where uncertainty persists, consultation with a veterinary internal medicine specialist is appropriate. Professional practice resources, such as those published by the American Veterinary Medical Association, can assist in locating specialist referral networks and current consensus statements.

The Role of Rescue and Adjunctive Therapies

When standard induction fails or the patient deteriorates rapidly, rescue options must be considered. Intravenous immunoglobulin (IVIG) provides rapid, though temporary, blockade of Fc receptors on macrophages, reducing antibody-mediated destruction within 24 to 48 hours. It is used as a bridging therapy in severe IMHA and ITP while slower-acting agents take effect. The human medicine literature includes case reports of IVIG combined with rituximab and splenic embolization in refractory autoimmune hemolytic anemia, and while these reports do not establish general rules for veterinary patients, they illustrate the logic of multimodal rescue in life-threatening cytopenias. Splenectomy is a further option in refractory IMHA or ITP, removing a major site of antibody production and phagocytosis, though it carries surgical and infectious risks.

The decision to escalate to rescue therapy should be made against explicit criteria: continued hemolysis or bleeding despite adequate glucocorticoid and second-line therapy, transfusion dependence, or the development of life-threatening complications such as thromboembolism. These criteria should be documented in the medical record so that the response to rescue can be assessed objectively.

Monitoring and Tapering Strategy

Monitoring serves two purposes: assessing disease control and detecting drug toxicity. During induction, a complete blood count, biochemistry panel, and urinalysis should be repeated every 1 to 2 weeks until the disease is stable. For cytopenic diseases, the platelet count or hematocrit is the primary efficacy parameter. For polyarthritis, lameness scores and joint cytology guide decisions. For pemphigus, lesion counts and surface area estimates are used. Blood pressure should be checked regularly in dogs on glucocorticoids, and urine protein-to-creatinine ratios are indicated when glomerular disease is present or suspected.

Tapering should begin only after the disease has been stable for at least 2 to 4 weeks. The glucocorticoid dose is reduced stepwise, typically by 20% to 25% every 2 to 4 weeks, while the steroid-sparing agent is maintained at its full dose. If relapse occurs, the dose is increased to the last effective level and the taper is restarted more slowly. The steroid-sparing agent is tapered only after glucocorticoids have been withdrawn or reduced to physiologic levels. Premature withdrawal is the most common cause of relapse, and owners must understand that therapy often continues for 6 to 12 months or longer. The Davis-Thompson Foundation pathology resources provide useful case material for recognizing the histologic patterns of immune-mediated disease and for confirming relapse when clinical signs are ambiguous.

Establishing the Diagnosis Before Therapy

The decision to start immunosuppressive therapy commits the patient to weeks or months of drug exposure with measurable risk. That commitment is justified only when the evidence for immune-mediated disease is strong enough to exclude differentials that would demand different treatment. The diagnostic sequence therefore moves from minimum database to disease-specific testing, with the pace determined by clinical stability.

For suspected immune-mediated hemolytic anemia (IMHA), the minimum database includes a complete blood count with manual smear review, serum biochemistry, and urinalysis. The smear is non-negotiable. It distinguishes true agglutination from rouleaux, identifies spherocytes, and screens for blood parasites or Heinz bodies that would redirect the diagnosis. A saline agglutination test performed on a fresh blood sample at room temperature and at 37°C provides rapid supportive evidence when spherocytosis is present. For immune thrombocytopenia (ITP), platelet clumping on the smear is the most common false-positive trigger for thrombocytopenia, and a manual count from a fresh sample often resolves the question before any therapy is considered.

Flow cytometry-based direct antiglobulin testing has been evaluated in dogs with suspected ITP, with a diagnostic cutoff of 10% IgG-bound platelets distinguishing affected from healthy dogs in one study population. The same study found that DAT-positive dogs had significantly lower platelet counts than DAT-negative dogs, supporting the test's correlation with disease severity. However, the test is not universally available, and its sensitivity and specificity in general practice populations remain incompletely defined. Where flow cytometric DAT is unavailable, the diagnosis rests on compatible clinical findings, exclusion of other causes, and response to therapy.

The decision to treat is time-sensitive in the unstable patient. A dog with pallor, tachycardia, and a rapidly falling hematocrit cannot wait for confirmatory serology. In that setting, treatment begins when the pretest probability of immune-mediated disease is high and the consequences of delayed therapy outweigh the risks of empirical immunosuppression. The reverse applies to the stable thrombocytopenic dog with no bleeding signs: here the clinician has time to pursue infectious disease testing, imaging, and serial platelet counts before committing to immunosuppression.

Selecting First-Line Therapy by Disease Category

The glucocorticoid remains the anchor of induction therapy across canine autoimmune diseases, but the choice of adjunctive agent depends on the target tissue, the severity of presentation, and the anticipated time to response. The table below summarizes the decision framework.

The evidence base for these choices is largely extrapolated from human medicine and from retrospective canine case series. Prospective comparative trials are scarce, and the clinician should expect that individual responses vary. The MSD Veterinary Manual provides species-specific guidance on drug selection and monitoring that should be consulted alongside current formularies.

Monitoring Response and Adverse Effects

Monitoring serves two simultaneous purposes: confirming that the therapy is working and detecting drug toxicity before it becomes irreversible. The frequency of monitoring reflects the half-life of the target cell line and the expected time to response.

For IMHA, the packed cell volume (PCV) is the primary response parameter. It should be measured daily during the first 3 to 5 days of hospitalization, then every 2 to 3 days until stabilization, and weekly thereafter during the taper. A rising PCV with declining reticulocytosis and resolution of agglutination indicates response. A falling PCV despite therapy demands reassessment of the diagnosis, consideration of transfusion, and escalation of immunosuppression. The reticulocyte count distinguishes regenerative from non-regenerative IMHA, and its trajectory predicts the timing of hematocrit recovery.

For ITP, the platelet count is the response parameter. A rise above 50,000/µL is generally associated with cessation of spontaneous bleeding, and counts above 100,000/µL allow safe reduction of immunosuppression. The flow cytometry DAT literature suggests that the percentage of IgG-bound platelets correlates inversely with platelet count, but serial DAT measurement during therapy has not been validated as a monitoring tool.

Adverse effect monitoring is drug-specific. Glucocorticoids require attention to gastrointestinal ulceration, pancreatitis, hepatopathy, and iatrogenic hyperadrenocorticism. Steroid-sparing agents each carry their own toxicity profile: mycophenolate can cause dose-dependent gastrointestinal signs, cyclosporine requires monitoring of trough levels where available, and leflunomide demands serial liver enzyme and complete blood count assessment. The AVMA practice resources include guidance on adverse event reporting and professional standards that apply when drug-related complications arise.

When to Escalate and When to Withdraw

Escalation is indicated when the primary response parameter fails to improve within the expected window, when the patient deteriorates despite therapy, or when a new disease manifestation appears. The expected window differs by disease: IMHA should show a trend toward stabilization within 3 to 5 days, ITP within 5 to 7 days, and pemphigus lesions within 2 to 4 weeks. Failure to meet these benchmarks triggers a three-step reassessment: confirm the diagnosis, exclude concurrent disease, and add or switch the steroid-sparing agent.

Withdrawal of therapy begins only after the disease is in remission, defined as a stable hematocrit or platelet count without transfusion support, or complete or near-complete resolution of skin lesions. The taper should be slow, typically over 2 to 4 months for glucocorticoids and longer for steroid-sparing agents, with each step followed by a 2-week observation period before the next reduction. Relapse during the taper returns the patient to the previous dose, not to the starting dose, and prompts reconsideration of the steroid-sparing agent choice.

The decision to stop therapy entirely rests on sustained remission at a low or alternate-day dose. Some dogs require lifelong maintenance, and the clinician should discuss this possibility with the owner before the taper begins. The Davis-Thompson Foundation pathology resources offer case material that illustrates the histologic spectrum of autoimmune disease and can support diagnostic confidence when the clinical picture is ambiguous.

Documentation and Communication

The treatment record should include the date of diagnosis, the diagnostic tests performed and their results, the induction protocol with drug names and doses, the monitoring schedule, and each response parameter with its value and date. A flow sheet format works well for hospitalized patients, with columns for date, PCV, platelet count, reticulocyte count, drug doses, and clinical notes. This structure makes trends visible at a glance and reduces the risk of missing a slow deterioration.

Owner communication should cover the expected time to response, the monitoring schedule, the financial commitment, and the signs of drug toxicity that require immediate recheck. Written instructions are preferable to verbal advice, and the clinician should document that the owner received and understood them. The WOAH terrestrial animal health standards do not directly govern companion animal immunosuppression, but they reinforce the principle that treatment decisions should be recorded in a manner that supports continuity of care and professional accountability.

Recognized Complications and Early Detection

The principal failure modes in immunosuppressive therapy fall into four categories: infection, drug-specific toxicity, disease relapse, and thromboembolism. Each has a characteriztic temporal pattern that informs the monitoring schedule.

Infection is the most common cause of treatment-related death. Bacterial pneumonia, urinary tract infection, and sepsis dominate, with opportunistic fungal disease emerging in dogs receiving prolonged combination therapy. Detect infection before clinical decompensation by measuring temperature at every visit, inspecting mucous membranes, and asking owners specifically about cough, lethargy, and urine odour. A complete blood count that shows new neutropenia or a degenerative left shift warrants immediate urine culture and thoracic imaging. Do not attribute fever to the underlying autoimmune disease until infection has been excluded by culture.

Glucocorticoid-specific toxicity includes panting, polyuria, polydipsia, hepatomegaly, and gastrointestinal ulceration. These effects are dose-dependent and predictable. Routine measurement of serum alkaline phosphatase and bilirubin at each recheck identifies steroid hepatopathy, which is benign, but a rising bilirubin with falling hematocrit suggests either immune-mediated hemolysis or gastrointestinal bleeding. Fecal occult blood testing and abdominal ultrasound discriminate between these possibilities.

Calcineurin inhibitors and mycophenolate produce gastrointestinal signs that often mimic disease relapse. Vomiting, diarrhea, and anorexia in a dog receiving ciclosporin should prompt a serum trough level if the assay is available, because toxicity correlates with supratherapeutic concentrations. Drug intolerance is managed by dose reduction or dividing the daily dose, not by abandoning immunosuppression without a replacement plan.

Thromboembolism, particularly pulmonary thromboembolism, is an under-recognized cause of sudden deterioration in immune-mediated hemolytic anemia. Tachypnoea, anxiety, and refractory hypoxemia in a dog whose hematocrit is stabilizing should raise suspicion. Thoracic radiographs may be normal, arterial blood gas analysis and echocardiography are more sensitive. Anticoagulant prophylaxis is considered in high-risk patients, but the evidence base in veterinary medicine remains limited.

Common Errors and Corrective Actions

The most frequent error is treating a presumptive diagnosis without adequate confirmation. A dog with thrombocytopenia and no other findings may have infectious, neoplastic, or drug-induced disease. The flow cytometry-based direct antiglobulin test described in a 2026 study of 1127 thrombocytopenic dogs identified platelet-bound IgG in 39.3% of cases, with DAT-positive dogs having significantly lower platelet counts than DAT-negative dogs. This test can support the diagnosis, but it does not replace a thorough search for underlying causes. Corrective action: complete baseline infectious disease testing, imaging, and bone marrow evaluation before committing to long-term immunosuppression.

A second error is tapering too quickly once clinical remission is achieved. Relapse rates increase when glucocorticoids are reduced by more than 25% per week or when the steroid-sparing agent is discontinued before the glucocorticoid has been fully withdrawn. Corrective action: extend the taper interval and reduce the increment when the dose approaches physiologic range.

A third error is adding a second immunosuppressive drug without a clear indication. Combination therapy increases infection risk and cost without guaranteed benefit. Use a steroid-sparing agent when glucocorticoid requirements are excessive, when adverse effects are intolerable, or when the disease is refractory to glucocorticoids alone.

Troubleshooting Table

Limitations of Evidence and Areas of Expert Disagreement

The veterinary literature on immunosuppressive therapy consists largely of retrospective studies and small prospective trials. Randomised controlled comparisons of steroid-sparing agents are scarce, and no consensus exists on which agent is superior for a given disease. Expert opinion differs on the role of multi-agent induction therapy, the optimal duration of maintenance therapy, and the value of therapeutic drug monitoring for mycophenolate.

The organ-on-chip systems described in a 2025 review represent an emerging approach to modeling individual immune responses, but these platforms are not yet clinically available for canine patients. Their potential to inform immunotherapy selection in precision medicine is promising, yet current therapeutic decisions rest on clinical judgment and serial monitoring instead of predictive laboratory assays.

Referral, Consultation, and Reporting

Referral to a veterinary internal medicine specialist is warranted when the diagnosis is uncertain after initial evaluation, when the disease is refractory to first-line therapy, when relapse occurs during an appropriate taper, or when the patient develops a serious adverse event. Specialist consultation is also appropriate before initiating rescue therapies such as plasmapheresis or splenectomy.

Clinical pathologists should be involved early when cytopenias are unexplained, when atypical cells are identified, or when bone marrow evaluation is required. The educational pathology resources provided by the Davis-Thompson Foundation offer case material that can support diagnostic reasoning in challenging hematologic cases.

Regulatory reporting obligations vary by jurisdiction. Report suspected adverse drug reactions to the relevant national pharmacovigilance program, and consult the WOAH terrestrial animal health standards for notifiable disease requirements. The MSD Veterinary Manual and AVMA practice resources provide additional guidance on professional obligations and standard of care.

Frequently Asked Questions

How Do I Manage Immunosuppressive Therapy When the Owner Has Severe Cost Constraints?

Prioritize interventions by diagnostic and therapeutic yield. A minimum database with platelet count, packed cell volume, and a manual blood smear review often costs less than a single week of advanced immunosuppression and prevents fruitless therapy. Glucocorticoids remain the most cost-effective first-line agent. If a steroid-sparing drug is unaffordable, discuss a longer glucocorticoid course with closer monitoring for proteinuria, pancreatitis, and infection. Mycophenolate and leflunomide differ in price between formulations and regions, so request dispensing quotes before committing. Referral for advanced diagnostics may be inappropriate when funds are limited. Instead, use serial physical examination and repeat minimum laboratory work to guide tapering. Document the financial discussion in the record, including the owner's informed acceptance of a less intensive protocol.

What Should I Do When Flow Cytometry or Advanced Coagulation Testing Is Unavailable?

Diagnosis rests on compatible clinical signs, thrombocytopenia or anemia, and exclusion of other causes. A flow cytometric direct antiglobulin test adds diagnostic confidence but is not required to start therapy when hemorrhage or severe anemia demands intervention. In-house blood smear evaluation for spherocytes, schistocytes, and platelet clumping remains the first-line tool. If platelet-bound antibody testing is unavailable, document the response to a glucocorticoid trial over 48 to 72 hours as a pragmatic diagnostic indicator. The MSD Veterinary Manual provides species-specific guidance on interpreting basic hematologic findings. When clinical signs progress despite appropriate therapy, referral to a center with flow cytometry may clarify the diagnosis, as described in a study of canine immune thrombocytopenia using a flow cytometry-based direct antiglobulin test diagnostic evaluation of a flow cytometry-based direct antiglobulin test in dogs.

How Does My Approach Change for a Cat or an Exotic Species?

This framework is written for dogs. Cats metabolise glucocorticoids differently and are more prone to steroid-induced diabetes mellitus and skin fragility, so dose intensity and monitoring intervals must be adjusted. Exotic species, including ferrets and rabbits, have distinct drug metabolism and a higher risk of gastrointestinal injury with nonsteroidal anti-inflammatory drugs, which are not part of autoimmune therapy. Always consult a species-specific formulary before prescribing. The MSD Veterinary Manual and AVMA practice resources offer cross-species guidance. If you lack experience with the target species, contact a specialist before initiating immunosuppression. Document the species-specific rationale for drug choice and monitoring in the medical record.

What Records Should I Keep for a Patient on Long-Term Immunosuppression?

Maintain a problem list, a drug chart with start dates and dose changes, and a monitoring log that includes body weight, blood pressure, urinalysis, and serum chemistry results. Record the tapering schedule and the reason for each dose adjustment. Note any adverse event with its date, severity, and corrective action. If the patient is a breeding animal, record the discussion about heritability and the recommendation against breeding. For insured patients, itemised invoices and a clinical summary letter help owners claim benefits. The AVMA practice resources include guidance on medical record standards. Clear records also support continuity when a different clinician assumes care during an emergency or after referral.

How Do I Explain the Diagnosis and Treatment Plan to a Client Who Is Anxious About "Steroids"?

Use the terms immunosuppression and immune modulation instead of steroids alone. Explain that the immune system is attacking the patient's own cells, and the goal is to dampen that attack, not to eliminate the immune system. Describe the expected timeline: visible improvement in days to weeks, then a slow taper over months. List the common adverse effects, including increased thirst, appetite, and urination, and explain which signs require a call. Provide a written summary of the monitoring schedule. The MSD Veterinary Manual offers client-accessible summaries that can reinforce your explanation. Reassure the owner that most patients tolerate therapy well when monitored, and that abrupt discontinuation is the main avoidable risk.

When Should I Seek a Second Opinion or Referral?

Refer when the diagnosis is uncertain after initial evaluation, when the patient fails to respond to an adequate glucocorticoid trial within 72 to 96 hours, or when a steroid-sparing agent is needed but you lack experience with it. Refer also when the patient develops an adverse event you have not managed before, such as steroid-induced pancreatitis or refractory proteinuria. If the patient is deteriorating and rescue therapy is required, contact a specialist while continuing supportive care. The Davis-Thompson Foundation provides pathology case material that can support difficult diagnostic reviews. A second opinion is not a failure of care. It is a documented step that protects the patient and clarifies the therapeutic path.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• My cells, my model: immune-competent autologous organ-on-chip systems as a new paradigm in precision medicine.. 2025.
• Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia.. 2013.
• Diagnostic evaluation of a flow cytometry-based direct antiglobulin test and demographic analysis in dogs with suspected immune thrombocytopenia.. 2026.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Therapeutic Decision-Making for Bacterial Skin Infections in Dogs
• Therapeutic Decision-Making for Urinary Tract Infections in Dogs
• Therapeutic Decision-Making for Gastrointestinal Ulcers in Veterinary Patients
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Autoimmunity: Mechanisms and Veterinary Examples

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.